F18-fluorodeoxyglucose positron emission tomography/computed tomography for bone hemangiopericytoma

Bone hemangiopericytoma (HPC) is extremely rare, and its clinical manifestations and radiographic features are nonspecific. There are few case reports about application of F18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in HPC. A total of four subjects with pat...

Full description

Saved in:
Bibliographic Details
Published inMolecular and clinical oncology Vol. 7; no. 6; pp. 1147 - 1151
Main Author Liu, Yiyan
Format Journal Article
LanguageEnglish
Published England D.A. Spandidos 01.12.2017
Spandidos Publications
Spandidos Publications UK Ltd
Subjects
Autoimmune diseases
bone hemangiopericytoma
Care and treatment
Chemotherapy
Diagnosis
F18-fluorodeoxyglucose positron emission tomography/computed tomography
Hemangiopericytoma
Hospice care
Hypocalcemia
Laboratories
Medical imaging
Medical records
Metabolism
Metastasis
Oncology
paraneoplastic syndrome
Pathology
Patients
Positron emission tomography
Software
Surveillance
Tomography
Tumors
Urine
F18-fluorodeoxyglucose positron emission tomography/computed tomography
bone hemangiopericytoma
hypocalcemia
paraneoplastic syndrome
Online AccessGet full text

Cover

More Information
Summary:Bone hemangiopericytoma (HPC) is extremely rare, and its clinical manifestations and radiographic features are nonspecific. There are few case reports about application of F18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in HPC. A total of four subjects with pathologically diagnosed bone HPC had FDG PET/CT for staging and/or restaging bone HPC. Medical records were retrospectively reviewed for radiological, pathological and follow-up information. All primary bone and metastatic lesions demonstrated high FDG avidity on PET/CT, which also revealed the adjacent soft tissue involvement and synchronous lesion. PET/CT correctly detected metastatic lesions in 1 patient. Furthermore, 3/4 patients with available laboratory data had hypocalcemia, but normal phosphorus levels when HPC existed as primary lesions or metastatic disease; however, normalization of calcium levels when they were disease-free. The results suggested that FDG PET/CT could be effectively used for staging, surveillance and detection of recurrent/metastatic disease in HPC. There may be an association between bone HPC and hypocalcemia.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2017.1458